Skip to main content
Nancy Lin, MD, Oncology, Boston, MA

NancyUan-TsinLinMD

Oncology Boston, MA

Breast Cancer

Associate Professor of Medicine, Harvard Medical School; Associate Chief, Division of Breast Oncology Center, Dana-Farber Cancer Institute

Dr. Lin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lin's full profile

Already have an account?

  • Office

    44 Binney St
    # Dana-Far
    Boston, MA 02115
    Phone+1 617-632-3800
    Fax+1 617-632-1930

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2002
  • Harvard Medical School
    Harvard Medical SchoolClass of 1999

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • VT State Medical License
    VT State Medical License 2023 - 2026
  • MA State Medical License
    MA State Medical License 2002 - 2025
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Attitudes of Patients with Metastatic Cancer Towards Research Biopsies  
    Nancy Lin, MD, Asia‐Pacific Journal of Clinical Oncology

Press Mentions

  • Managing Central Nervous System Metastasis in Patients with HER2-Positive Breast Cancer
    Managing Central Nervous System Metastasis in Patients with HER2-Positive Breast CancerOctober 22nd, 2024
  • T-dXd Demonstrated Intracranial Activity in HER2+ Breast Cancer
    T-dXd Demonstrated Intracranial Activity in HER2+ Breast CancerOctober 5th, 2024
  • DESTINY-Breast12: T-dXd Exhibits Clinical Activity in HER2+ Breast Cancer Irrespective of Brain Metastases
    DESTINY-Breast12: T-dXd Exhibits Clinical Activity in HER2+ Breast Cancer Irrespective of Brain MetastasesSeptember 30th, 2024
  • Join now to see all

Professional Memberships